Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.
Treatment Options for HCV Patients with Renal Impairment
A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.
Safety of New HCV Direct-Acting Antivirals Called into Question
A report warns that liver failure might be associated with nine new direct-acting antivirals (DAA).
Too Many Conflicts of Interest Found in HCV Management Guidelines
A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.
Gilead's Combination Therapy for HCV Has Been Validated by The EMA
The European Medicines Agency has fully validated Gilead’s SOf/VEL/VOX regimen to treat hepatitis C (HCV).
Is Interferon Therapy Behind Cognitive Decline in HCV Patients?
Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of patients in a study published in Neurology in December 2016.
HCV Treatment Achieves Viral Suppression in Less Than 12 Weeks
Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.
Class-Action Lawsuit Filed Against Insurance Company Over Denied Harvoni Coverage Dropped
Insurance companies are denying members coverage to expensive drugs, like Harvoni, and those infected with HCV are filing lawsuits.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.